Inhaled Nitric Oxide (NO) Delivery Systems Market Size, Share & Industry Analysis, By Application (Adult, Infant), By Type (General, Intelligent), By End-User (Hospitals, Clinics, Specialty Centres, Others) and Regional Forecast, 2024-2032

Inhaled Nitric Oxide (NO) Delivery Systems are devices used for deliverng nitric oxide in paients experiencing severe breathing problems. Nitric oxide is clinically efficient  in dilating bloood vessels and to relax muscle tension in order to abosrb oxgen efficiently in the body. Additionally, the nitric oxide delivery systems are also used to treat hypoxic respiratory failure in infants. Focus of key players to launch technologically advanced NO delivery systems combined with the rise of respiratory diseases are estimated to bolster the market growth in the coming years. For example, in January 2020, Vero Biotech LLC received U.S FDA clearance for GENOSYL inhaled nitric oxide gas delivery system.

Increase in the incidence and prevalence of respiratory disease are estimated to fuel the inhaled nitric oxide (NO) market growth over the forecast duration. In addition to this increase outbreak of respiratory infections like SARS, COVID-19 among others is further projected to drive the NO delivery systems market. As of May 2020, around 1.8 million people are affected with coronavirus in the U.S. Moreover, the U.S FDA has permitted the emergency use of GENOSYL NO delivery system manufactured by VERO Biotech in critical COVID-19 patients suffering from respiratory failure. These trends are expected to surge the demand of inhaled nitric oxide delivery systems in the country.

However, product recalls of inhaled nitric oxide delivery systems are estimated to restrain the market growth in the coming years. For instance, in November 2016, Mallinckrodt Pharmaceuticals has to recall INOmax DSIR Plus delivery system owing to defective valve calibration of the manometer. The U.S FDA classified the recall as Class 2 device recall.

Market Segmentation:

Globally, the inhaled nitric oxide (NO) delivery systems market can be categorized on the basis of application, type, end-user and region. Based on the application, the market can be segmented into adult and infant. Based on the type, the market can be bifurcated into intelligent and general. Based on the end-users the market can be segmented into hospitals, clinics, specialty centres, and others.

Geographically, the inhaled nitric oxide (NO) delivery systems market can be segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

Key Players Covered:

Some of the major companies that are present in the inhaled nitric oxide (NO) delivery systems market are VERO Biotech LLC, International Biomedical, Bellerophon Therapeutics, Mallinckrodt Pharmaceuticals, Praxair, Inc., SLE, Getinge AB, and other prominent players.

Key Insights:

• Prevalence of Respiratory Disease  by Key Countries/Region


• Technological Advancements in Inhaled Nitric Oxide Delivery Systems Market by Key Countries/Region


• Introduction of New Products/Approvals (By Major Players)


• Key Industry Developments Mergers, Acquisitions, and Collaborations

Regional Analysis:

Based on geographical segmentation, the inhaled nitric oxide (NO) delivery systems market can be categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North American region is projected to hold the leading position in the market and is anticipated to follow the same impetus over the forecast duration. This growth of the market can be owing to the higher awareness regarding respiratory illness and disorders combined with refined healthcare infrastructure in the region. Moreover, increase in the prevalence of the chronic diseases and availability & high adoption of technologically advanced products are also driving the market in this region. Introduction of advanced NO delivery systems in the region is also estimated to aid the market growth. In August 2019, Beyond Air announced the development of LungFit PH, an innovative cylinder free NO delivery system for patients suffering from pulmonary hypertension. Europe is projected to be the second most dominant market throughout the analysis duration. The factors such as increases in the prevalence of chronic diseases, and rise in geriatric population and adoption of innovative medical devices is projected to drive the inhaled nitric oxide (NO) delivery systems market growth in this region. However, the countries of Asia-Pacific region is likely to expand at comparatively higher growth rate in near future. The growth of the market can be attributed to the increase in respiratory failure, outbreak of respiratory infections and rise in geriatric population. The Latin America and the Middle East and Africa markets are expected to expand at a moderate rate during the forecast period.

Segmentation

Inhaled Nitric Oxide (NO) Delivery Systems Market Industry Developments

• In March 2020, Mallinckrodt Pharmaceutical received approval from the regulatory authorities of Canada to use the company’s NO delivery systems for COVID-19 patients


• In March 2020, the U.S FDA approved the emergency expanded use of inhaled nitric oxide delivery system manufactured by Bellerophon Therapeutics for the management of respiratory failure in COVID-19 patients.